• Publications
  • Influence
Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use
Mupirocin (pseudomonic acid A), an antibiotic produced by Pseudomonas fluorescens, showed a high level of activity against staphylococci and streptococciand against certain gram-negative bacteria, but was much less active against most gram- negative bacilli an anaerobes.
Flucloxacillin, a New Isoxazolyl Penicillin, Compared with Oxacillin, Cloxacillin, and Dicloxacillin
Compared with isoxazole penicillins in current clinical use, flucloxacillin has proved as active against Gram-positive cocci, including penicillin-resistant staphylococci, and is well absorbed in man after oral and intramuscular administration.
The binding of antibiotics to serum proteins.
On certain aspects, published data are available but are conflicting and some lack of agreement exists on the precise extent of binding of certain antibiotics, particularly of tetracyclines.
Carbenicillin: a new semisynthetic penicillin active against Pseudomonas pyocyanea.
Carbenicillin (disodium a-carboxybenzylpenicillin; BRL 2064) is a new semisynthetic penicillin with a wide spectrum of activity against Gram-positive and Gram-negative bacteria. In particular,
BRL 17421 , a Novel f ,-Lactam Antibiotic , Highly Resistant to , 8-Lactamases , Giving High and Prolonged Serum Levels in Humans
The compound exhibits exceptional stability to a wide range of bacterial /8-lactamases and is active against the majority of Enterobacteriaceae, including strains highly resistant to many of the penicillins and cephalosporins currently available.
Cultures of naturally occurring methicillin-resistant staphylococci obtained from a number of hospitals were examined for the nature and degree of resistance to methiillin and other antibiotics.
BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans
The compound was well tolerated after intramuscular and intravenous administration in volunteers, with no adverse side effects, and was markedly less active against Pseudomonas aeruginosa and Bacteroides fragilis than against the Enterobacteriaceae.
Development of beta-lactamase inhibitors.
  • R. Sutherland
  • Biology, Medicine
    The Journal of reproductive medicine
  • 1 March 1990
The success of clavulanic acid has confirmed beta-lactamase inhibitors as one solution to the problem of antibiotic-resistant bacteria.